Shark Tank India 3: Namita Thapar becomes a solo investor in Cervical Cancer self-sampling brand; pitchers choose her over Ritesh Agarwal

Sayantani introduces a patented self-sampling kit for private collection, seeking Rs 75 Lakhs for 1.5% equity. Approved by FDA after trials, with background and vision shared. Namita and Ritesh offer investment with conditions.